A Pediatric Case of Sensory Predominant Guillain-Barré Syndrome Following  COVID-19 Vaccination

Zhu, Zahra; Kochar, Puneet; Gavigan, Patrick; Kaur, Divpreet; Kumar, Ashutosh

doi:10.1177/2329048x221074549

Cited by 14 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 100 case reports or case series which reported cardiac complications after COVID-19 vaccination were included 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , …”

Section: Resultsmentioning

confidence: 99%

Cardiovascular complications of COVID-19 vaccines: A review of case-report and case-series studies

2023

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Cardiovascular complications of COVID-19 vaccines: A review of case-report and case-series studies

2023

View full text Add to dashboard Cite

“…1 ). All of the included articles are tabulated ( Table 1 ) [ 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 ]. We have excluded one case each from the case series of Bonafacio et al [ 39 ] and Osowicki et al [ 60 ] and four patients from the case series of Garcia-Grimshaw et al [ 69 ] from the final analysis due to the confounding factors implicated in the causation of GBS ( Supplement 3 ).…”

Section: Resultsmentioning

confidence: 99%

Guillain-Barré syndrome associated with SARS-CoV-2 vaccination: how is it different? a systematic review and individual participant data meta-analysis

Reddy,

Murthy,

Osman

et al. 2023

Clin Exp Vaccine Res

View full text Add to dashboard Cite

Purpose An association between Guillain-Barré syndrome (GBS) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination has been reported. We aimed to summarize the clinical features of GBS associated with SARS-CoV-2 vaccination and determine the contrasting features from coronavirus disease-19 (COVID-19) associated GBS and GBS following other causes. Materials and Methods We performed PubMed search for articles published between 1 December 2020 and 27 January 2022 using search terms related to “SARS-CoV-2 vaccination” and “GBS”. Reference searching of the eligible studies was performed. Sociodemographic and vaccination data, clinical and laboratory features, and outcomes were extracted. We compared these findings with post-COVID-19 GBS and International GBS Outcome Study (IGOS) (GBS from other causes) cohorts. Results We included 100 patients in the analysis. Mean age was 56.88 years, and 53% were males. Six-eight received non-replicating virus vector and 30 took messenger RNA (mRNA) vaccines. The median interval between the vaccination and the GBS onset was 11 days. Limb weakness, facial palsy, sensory symptoms, dysautonomia, and respiratory insufficiency were seen in 78.65%, 53.3%, 77.4%, 23.5%, and 25%, respectively. The commonest clinical and electrodiagnostic subtype were sensory-motor variant (68%) and acute inflammatory demyelinating polyneuropathy (61.4%), respectively. And 43.9% had poor outcome (GBS outcome score ≥3). Pain was common with virus vector than mRNA vaccine, and the latter had severe disease at presentation (Hughes grade ≥3). Sensory phenomenon and facial weakness were common in vaccination cohort than post-COVID-19 and IGOS. Conclusion There are distinct differences between GBS associated with SARS-CoV-2 vaccination and GBS due to other causes. Facial weakness and sensory symptoms were commonly seen in the former and outcomes poor.

show abstract

“…GBS has been associated with in uenza [4] and COVID-19 vaccinations [5]. GBS has been reported following Moderna [6][7][8][9][10], P zer BioNTech BNT162b2 [11][12][13][14][15][16][17][18][19], Oxford AstraZeneca ChAdOx1 day [15,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34], Johnson & Johnson/Janssen Ad26.CoV2.S [10,[35][36][37][38][39], Sinopharm [33,34], and Sputnik V [34,40] COVID-19 vaccines. Many GBS patients are expected as sporadic cases and should not be considered causal [41].…”

Section: Introductionmentioning

confidence: 99%

Pain Adverse Events, Bell’s Palsy, and Guillain-Barré Syndrome Following Vaccination

Ricke¹

2022

J Mod Biol Drug Discov

View full text Add to dashboard Cite

ObjectiveSome individuals (vaccinees) experience pain related adverse events following vaccinations. The majority of these pain related vaccination reactogenicity adverse events resolve within days. Rare adverse events like Bell's palsy and Guillain-Barré syndrome (GBS) have been associated with some vaccines. Herein, multiple working hypotheses are examined in the context of available characteristics of vaccinees and onset of these pain related adverse events post vaccination. MethodsThe Vaccine Adverse Event Reporting System (VAERS) database was datamined for pain associated vaccine adverse events data by vaccine, age, gender, dose, and onset post vaccination. Results for vaccines with the highest number of pain related adverse events were compared. ResultsFor the pain related adverse events examined, the highest number of adverse events are reported within 1 day, roughly half this number the second day, and roughly a quarter this number by the third day. The day of onset for these pain related adverse events approximates a power of two decay pattern for the rst three days. This same pattern is observed for all of the vaccines with the highest number of pain related adverse events. The consistency of these day of onset frequency patterns of examined adverse events following vaccinations for multiple unrelated vaccines enables the exclusion of speci c vaccine components and excipients as speci cally causative entities. ConclusionThe observed onset occurrences of examined pain associated adverse events are consistent with likely etiology relationship with innate immune responses to vaccinations for multiple vaccines including SARS-CoV-2 COVID-19, in uenza, and additional vaccines. Innate immune responses may be contributing to the initial etiology of Bell's palsy and GBS post SARS-CoV-2 mRNA and adenoviral vaccinations.

show abstract

A Pediatric Case of Sensory Predominant Guillain-Barré Syndrome Following COVID-19 Vaccination

Cited by 14 publications

References 15 publications

Cardiovascular complications of COVID-19 vaccines: A review of case-report and case-series studies

Cardiovascular complications of COVID-19 vaccines: A review of case-report and case-series studies

Guillain-Barré syndrome associated with SARS-CoV-2 vaccination: how is it different? a systematic review and individual participant data meta-analysis

Pain Adverse Events, Bell’s Palsy, and Guillain-Barré Syndrome Following Vaccination

Contact Info

Product

Resources

About